Skip to main content

Building patient-focused companies around transformative technologies.

Hibiscus BioVentures provides the Technology, Capital and People necessary to build transformative biotechnology companies.

Our Mission

Committed to significantly moving patient care forward by supporting development of commercially viable therapeutics and diagnostics. Providing all the resources necessary in-house to identify major unmet medical needs and drive impactful solutions for patients.


Hibiscus Biotechnology Logo

Venture studio focused on building companies from the ground up around innovative technologies.

Hibiscus Capital Management Logo

Patient-focused venture capital arm investing in transformative biotechnology companies.

Our Latest News


Triumvira Immunologics Establishes Collaboration with Merck to Evaluate TAC01-HER2 Cell Therapy in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2-positive Solid Tumors

| All | No Comments
AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., Jan. 5, 2023 /PRNewswire/ -- Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells…
Cellectis partnership Image

First startup blooms from Mayo Clinic cell and gene therapy accelerator with $750M Cellectis partnership

| All, Mayflower BioVentures | No Comments
Seeds from Mayo Clinic’s cell and gene therapy accelerator Mayflower Bioventures have taken flight in a new biotech called Primera Therapeutics, which launches today with a blossoming $750 million partnership…
Gene Therapy

Mayo Clinic Joins With Industry Groups to Launch Biotech Accelerator

| All, Mayflower BioVentures | No Comments
Mayo Clinic has joined with two industry partners to start an accelerator for cell- and gene-therapy startups, part of an effort the healthcare provider is making to expand in this…